No Data
No Data
Insiders Were the Biggest Winners as Mabwell (Shanghai) Bioscience Co., Ltd.'s (SHSE:688062) Market Cap Grew by CN¥408m Last Week
Maiwei Biotech 2024 Semi-Annual Report
Summary of Maiwei Biotech\'s 2024 Semi-Annual Report
Maiwei Biology (688062.SH) has released its semi-annual performance, with a net loss of 0.445 billion yuan.
Ma Wei Bio (688062.SH) released its interim report for the first half of 2024, during the reporting period, the company achieved a revenue of 1.16...
Express News | Mabwell Announces Cde Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination With Pd-1 Inhibitor
MaWei Bio's targeted Nectin-4 ADC combined with PD-1 monoclonal antibody first-line treatment for urothelial carcinoma has been approved by the China Drug Evaluation Center (CDE) to conduct Phase III clinical trials.
Shanghai, August 26, 2024 / PRNewswire / - Mawei Bio (688062.SH), an innovative biopharmaceutical company with a complete industry chain layout, announced that its "A Phase III Clinical Study of 9MW2821 Combined with Toripalimab versus Standard Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma" has been approved by the Center for Drug Evaluation of the National Medical Products Administration (NMPA) and has initiated the first-line treatment of urothelial carcinoma in combination with PD-1 monoclonal antibody 9MW2821.
No Data
No Data